Dr. Ghoroghchian joined Poseida as chief technology officer in August 2018. He previously served as an attending physician in the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute and an instructor at Harvard Medical School. Dr. Ghoroghchian was also a Charles W. and Jennifer C. Johnson clinical investigator in the Koch Institute for Integrative Cancer Research at MIT, where he directed an independent research laboratory that developed technologies for biomedical imaging, drug delivery and gene editing. He earned his B.S. in chemical engineering from MIT in 1999, followed by Ph.D. and M.D. degrees from the University of Pennsylvania. After medical school, Dr. Ghoroghchian completed an internship and residency training in Internal Medicine at the Brigham and Women’s Hospital, as well as fellowship training in hematology and medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital. His investigations are further informed by his experience in the biotechnology industry; a co-founder and chief scientist at Vindico NanoBioTechnology Inc., Dr. Ghoroghchian has also overseen research efforts at PhenoTech Inc., and other firms.